Gu J, Wang Y, Zhang H, Gu H, Zhu H
Discov Oncol. 2025; 16(1):324.
PMID: 40088346
DOI: 10.1007/s12672-025-02093-2.
Fan Y, Ji X, Yuan K, Wu Q, Lou M
J Inflamm Res. 2025; 18:3333-3347.
PMID: 40078575
PMC: 11900795.
DOI: 10.2147/JIR.S509316.
Li Y, Fan C, Jiang F, Zhang J, Li Y, Jiang Y
J Cancer Res Clin Oncol. 2025; 151(3):104.
PMID: 40056237
PMC: 11890329.
DOI: 10.1007/s00432-025-06146-5.
Cai L, Guo X, Zhang Y, Xie H, Liu Y, Zhou J
Sci Rep. 2025; 15(1):7986.
PMID: 40055390
PMC: 11889094.
DOI: 10.1038/s41598-025-91761-y.
Que Y, Ding T, Wang H, Xu S, He P, Shen Q
J Cell Mol Med. 2025; 29(5):e70424.
PMID: 40045162
PMC: 11882394.
DOI: 10.1111/jcmm.70424.
Identifying perturbations that boost T-cell infiltration into tumours via counterfactual learning of their spatial proteomic profiles.
Wang Z, Farooq A, Chen Y, Bhargava A, Xu A, Thomson M
Nat Biomed Eng. 2025; .
PMID: 40044819
DOI: 10.1038/s41551-025-01357-0.
DNA-PKcs, a player winding and dancing with RNA metabolism and diseases.
Hou J, Lu M, Guo J, Wu J, Wang C, Zhou P
Cell Mol Biol Lett. 2025; 30(1):25.
PMID: 40038612
PMC: 11877767.
DOI: 10.1186/s11658-025-00703-z.
A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes.
Li Z, Chen L, Wei Z, Liu H, Zhang L, Huang F
Front Immunol. 2025; 16:1518102.
PMID: 40018029
PMC: 11866059.
DOI: 10.3389/fimmu.2025.1518102.
Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.
Liu M, Li L, Cao L, Li W, Gu X, Yang M
J Immunother Cancer. 2025; 13(2).
PMID: 39988347
PMC: 11848677.
DOI: 10.1136/jitc-2024-010947.
A novel HVEM-Fc recombinant protein for lung cancer immunotherapy.
Yao Y, Li B, Wang J, Chen C, Gao W, Li C
J Exp Clin Cancer Res. 2025; 44(1):62.
PMID: 39979981
PMC: 11841141.
DOI: 10.1186/s13046-025-03324-8.
Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer.
Chen Y, Liu S, Yin X
Am J Cancer Res. 2025; 15(1):217-232.
PMID: 39949922
PMC: 11815372.
DOI: 10.62347/QTWJ8918.
Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer.
Gu T, Qi H, Wang J, Sun L, Su Y, Hu H
Discov Oncol. 2025; 16(1):163.
PMID: 39934467
PMC: 11813846.
DOI: 10.1007/s12672-025-01930-8.
A new paradigm for cancer immunotherapy: targeting immunogenic cell death-related noncoding RNA.
Sun G, He L
Front Immunol. 2025; 15:1498781.
PMID: 39916954
PMC: 11798941.
DOI: 10.3389/fimmu.2024.1498781.
Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies.
Zhang W, Ge L, Zhang Y, Zhang Z, Zhang W, Song F
Eur J Med Res. 2025; 30(1):69.
PMID: 39905506
PMC: 11792708.
DOI: 10.1186/s40001-025-02326-8.
Deciphering the generation of heterogeneity in esophageal squamous cell carcinoma metastasis via single-cell multiomics analysis.
Sheng K, Chen J, Xu R, Sun H, Liu R, Wang Y
J Transl Med. 2025; 23(1):148.
PMID: 39905485
PMC: 11792320.
DOI: 10.1186/s12967-025-06154-6.
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S
Sci Rep. 2025; 15(1):4294.
PMID: 39905117
PMC: 11794704.
DOI: 10.1038/s41598-024-82218-9.
Timp2 loss-of-function mutation and TIMP2 treatment in a murine model of NSCLC: Modulation of immunosuppression and oncogenic signaling.
Peeney D, Kumar S, Singh T, Liu Y, Jensen S, Chowdhury A
Transl Oncol. 2025; 53:102309.
PMID: 39904284
PMC: 11846589.
DOI: 10.1016/j.tranon.2025.102309.
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.
Shao X, Zhao X, Wang B, Fan J, Wang J, An H
Theranostics. 2025; 15(5):1689-1714.
PMID: 39897552
PMC: 11780529.
DOI: 10.7150/thno.103636.
EXO1 is a key gene for lung-resident memory T cells and has diagnostic and predictive values for lung adenocarcinoma.
Li Z, Lin X, Yang Y, Tian M, Zhang L, Huang F
Sci Rep. 2025; 15(1):4002.
PMID: 39893221
PMC: 11787328.
DOI: 10.1038/s41598-025-88126-w.
ANKRD22 participates in the proinflammatory activities of macrophages in the colon cancer tumor microenvironment.
Wang X, Yang K, Yang B, Wang R, Zhu Y, Pan T
Cancer Immunol Immunother. 2025; 74(3):86.
PMID: 39891675
PMC: 11787111.
DOI: 10.1007/s00262-024-03930-z.